Mr Krayacich will be responsible for leading the company’s drug and business development for ganaxolone, an adult and pediatric epilepsy candidate in Phase II, and chelerythrine, a preclinical schizophrenia candidate.
Most recently, Mr Krayacich was with Novartis Pharmaceuticals where he served as global program head for the antidepressant agomelatine, and vice president and global head of neuroscience project management.
Stephen Bloch, chairman of the board of directors at Marinus, said: “We are pleased that John is taking the helm at Marinus, particularly at such a crucial stage of development of the company’s lead compound, ganaxolone, a new class of epilepsy treatment.”